

HR 7251

Hatch-Waxman Integrity Act of 2018

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Dec 11, 2018

Current Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Serv

Latest Action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Dec 11, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/7251>

Sponsor

Name: Rep. Flores, Bill [R-TX-17]

Party: Republican • **State:** TX • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Dec 11, 2018
Financial Services Committee	House	Referred To	Dec 11, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 S 3738	Identical bill	Dec 11, 2018: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Dec 11, 2018)

Hatch-Waxman Integrity Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.

Actions Timeline

- **Dec 11, 2018:** Introduced in House
- **Dec 11, 2018:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.